This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Bernardo M, Azanza JR, Rubio-Terrés C, Rejas J.Cost-effectiveness analysis of schizophrenia relapse prevention: an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain. Clinical Drug Investigation 26: 447-457, No. 8, 2006
Rights and permissions
About this article
Cite this article
Ziprasidone avoids schizophrenia relapse at reasonable cost. Pharmacoecon. Outcomes News 510, 5 (2006). https://doi.org/10.2165/00151234-200605100-00013
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605100-00013